1. Search Result
Search Result
Pathways Recommended: MAPK/ERK Pathway
Results for "

Pathway Inhibitors

" in MedChemExpress (MCE) Product Catalog:

1543

Inhibitors & Agonists

12

Screening Libraries

6

Fluorescent Dye

10

Biochemical Assay Reagents

74

Peptides

15

Inhibitory Antibodies

397

Natural
Products

47

Isotope-Labeled Compounds

6

Click Chemistry

12

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-171115

    GPR84 Aldose Reductase Metabolic Disease
    Pyrone-211 is a potent GPR84 agonist and AKR1C3 inhibitor. Pyrone-211 participates in an expanded polyamine pathway .
    Pyrone-211
  • HY-164145

    TGF-β Receptor Others Cancer
    CDD-1653 is a potent and selective BMPR2 inhibitor (IC50=2.8 nM). CDD-1653 reduces the ability of ATP to bind to the kinase domain of BMPR2, thereby affecting the phosphorylation of SMAD1/5/8 transcription factors, which play a key role in the BMP signaling pathway. CDD-1653 can be used to study diseases related to the BMP signaling pathway .
    CDD-1653
  • HY-150505

    Deubiquitinase Apoptosis Cancer
    DC-U4106 is a USP8 targeting inhibitor with the Kdvalue of 4.7 μM and the IC50 value of 1.2 μM. DC-U4106 can target the ubiquitin pathway and facilitate the degradation of Erα. DC-U4106 inhibits tumor growth with minimal toxicity and has the potential for the research of breast cancer .
    DC-U4106
  • HY-158102

    Histone Methyltransferase Cancer
    ORIC-944 is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer.
    ORIC-944
  • HY-150761

    Microtubule/Tubulin Apoptosis Cancer
    MY-875 is a competitive microtubulin polymerization inhibitor with an IC50 value of 0.92 μM. MY-875 inhibits microtubulin polymerization by targeting colchicine binding sites and activates the Hippo pathway. MY-875 induces apoptosis and has anticancer activity .
    MY-875
  • HY-158102A

    Histone Methyltransferase Cancer
    ORIC-944 TFA is the TFA salt form of ORIC (HY-158102). ORIC-944 TFA is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 TFA is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer .
    ORIC-944 TFA
  • HY-119711

    MMP Cancer
    NNGH is a stromelysin-1 (MMP-3) inhibitor. MMP-3 is both a direct transcriptional target and a necessary contributor of the Wnt/β-catenin signaling pathway. Matrix metalloproteinases (MMPs) play a well-defined role in later stages of tumor progression .
    NNGH
  • HY-B1876

    Acetolactate Synthase (ALS) Photosystem II Fungal Others
    Nicosulfuron is efficient, harmless, antifungal and selective herbicide belonging to the sulfonylurea family. Nicosulfuron is also a photosynthetic system inhibitor and inhibits acetolactate synthase (ALS) enzyme activity. Nicosulfuron degradation by Plectosphaerella cucumerina AR1 is glucose concentration dependent in planktonic lifestyle. Nicosulfuron enhances the glycolysis pathway and tricarboxylic acid cycle to improve the adaptability of sweet maize. Nicosulfuron reduces the synthesis of branched-chain amino acids (BCAAs), which is proming for maize cultivation .
    Nicosulfuron
  • HY-117229

    Drug Metabolite Cancer
    Sonidegib metabolite M48 is the main circulating metabolite of Sonidegib. Sonidegib is a hedgehog pathway inhibitor. M48 showed a much longer Tmax (60 h) than Sonidegib .
    Sonidegib metabolite M48
  • HY-156441

    SARS-CoV Infection
    SARS-CoV-2-IN-65 (compound 2f (81)) is a potent,orally active and reversible SARS-CoV-2 entry inhibitor. SARS-CoV-2-IN-65 inhibits the pseudovirus entry in a ACE2-dependent pathway, via mainly inhibiting RBD:ACE2 interaction and TMPRSS2 activity in Calu-3 cells .
    SARS-CoV-2-IN-65
  • HY-163507

    Anaplastic lymphoma kinase (ALK) Cancer
    ALK5-IN-79 (compound 57) is an ALK inhibitor with anticancer activity, by blocking TGF-β1/SMAD signaling pathway. ALK5-IN-79 attenuates the production of extracellular matrix (ECM) and deposition of collagen. ALK5-IN-79 exhibits adequate pharmacokinetic (PK) properties and good in vivo tolerance.
    ALK5-IN-79
  • HY-138979

    Lipoxygenase Others
    Lipoxygenin is a non-redox 5-lipoxygenase (5-LO) inhibitor with an IC50 of 5 μM. Lipoxygenin modulates the β-catenin-5-LO complex, inducing a decrease in β-catenin and 5-LO levels in the nucleus .
    Lipoxygenin
  • HY-10431
    SB-431542
    200+ Cited Publications

    Organoid TGF-β Receptor Apoptosis Cancer
    SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .
    SB-431542
  • HY-10431R

    Apoptosis TGF-β Receptor Organoid Cancer
    SB-431542 (Standard) is the analytical standard of SB-431542. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .
    SB-431542 (Standard)
  • HY-139534

    ROR Apoptosis Cancer
    ARI-1 is an inhibitor of receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitor. ARI-1 effectively inhibits aberrant ROR1 expression, which is associated with the development of non-small cell lung cancer (NSCLC) and EGFR-TKI-induced drug resistance. ARI-1 binds to the extracellular Frizzled domain of ROR1 and regulates PI3K/AKT/mTOR signaling in a ROR1-dependent manner. ARI-1 potently inhibits NSCLC cell proliferation and migration and has antitumor activity in vivo [1] .
    ARI-1
  • HY-153750

    Wnt Cancer
    Wnt pathway inhibitor 3 is a potent wnt inhibitor with an IC50 value of 45 nM. Wnt pathway inhibitor 3 shows antiproliferative activity .
    Wnt pathway inhibitor 3
  • HY-169730

    Wnt Cancer
    Wnt pathway inhibitor 5 (Compound 28) is wnt pathway inhibitor, with an IC50 value of < 0.003 μΜ. Wnt pathway inhibitor 5 inhibits many cancers, including ovarian teratocarcinoma cancer, breast cancer, osteosarcoma, head and neck squamous carcinoma .
    Wnt pathway inhibitor 5
  • HY-N10472

    STAT Cancer
    STAT3-IN-14 (Compound 1) is a STAT3 inhibitor and has STAT3 phosphorylation inhibitory activity. STAT3-IN-14 (Compound 1) can directly bind to the hinge region of STAT3 .
    STAT3-IN-14
  • HY-160657

    YAP Others
    DC-TEADin04 has weak inhibitory activity against TEAD4 palmitoylation .
    DC-TEADin04
  • HY-112670
    Exo1
    4 Publications Verification

    Arf Family GTPase Others
    Exo1 is a chemical inhibitor of the exocytic pathway.
    Exo1
  • HY-129426

    Akt Cancer
    PDK1/Akt/Flt dual pathway inhibitor is one of a component of KP372-1 (HY-15673 ), and inhibits PDK1/Akt/Flt dual pathway .
    PDK1/Akt/Flt dual pathway inhibitor
  • HY-133558
    VII-31
    1 Publications Verification

    E1/E2/E3 Enzyme Apoptosis Cancer
    VII-31 is a potent NEDDylation pathway activator to inhibit the tumor progression in vitro and in vivo. VII-31 induces apoptosis via intrinsic and extrinsic pathways .
    VII-31
  • HY-101275
    EMT inhibitor-1
    2 Publications Verification

    Hippo (MST) TGF-beta/Smad Wnt Cancer
    EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities.
    EMT inhibitor-1
  • HY-12238
    IWR-1
    40+ Cited Publications

    endo-IWR 1; IWR-1-endo

    Organoid Wnt Cancer
    IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin signaling pathway.
    IWR-1
  • HY-13324
    Bardoxolone methyl
    25+ Cited Publications

    RTA 402; NSC 713200; CDDO Methyl ester

    Keap1-Nrf2 Autophagy Apoptosis Ferroptosis Cancer
    Bardoxolone methyl (NSC 713200; RTA 402; CDDO Methyl ester) is a synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities, acting as an activator of the Nrf2 pathway and an inhibitor of the NF-κB pathway.
    Bardoxolone methyl
  • HY-A0293
    Pyrvinium pamoate
    10+ Cited Publications

    Pyrvinium embonate

    Wnt Cancer
    Pyrvinium pamoate is an FDA-approved antihelmintic agent that inhibits WNT pathway signaling.
    Pyrvinium pamoate
  • HY-N1447
    Ganoderic acid A
    5+ Cited Publications

    Apoptosis Autophagy Endogenous Metabolite Cancer
    Ganoderic acid A can inhibit of the JAK-STAT3 signaling pathway, also inhibit proliferation, viability, ROS.
    Ganoderic acid A
  • HY-13307
    JK184
    2 Publications Verification

    Hedgehog Cancer
    JK184 is a potent Hedgehog (Hh) pathway inhibitor with IC50 of 30 nM in mammalian cells.
    JK184
  • HY-13901
    GANT 61
    55+ Cited Publications

    NSC 136476

    Gli Autophagy Cancer
    GANT 61 is an inhibitor of Gli1 and Gli2 targeting the Hedgehog/GLI pathway.
    GANT 61
  • HY-112108
    Chitosan oligosaccharide
    4 Publications Verification

    COS

    AMPK Endogenous Metabolite Metabolic Disease Cancer
    Chitosan oligosaccharide (COS) is an oligomer of β-(1→4)-linked D-glucosamine. Chitosan oligosaccharide (COS) activates AMPK and inhibits inflammatory signaling pathways including NF-κB and MAPK pathways.
    Chitosan oligosaccharide
  • HY-149414

    Microtubule/Tubulin Apoptosis ERK TGF-beta/Smad Cancer
    MY-673 is a colchicine binding site inhibitor (CBSI), that inhibits tubulin polymerization. MY-673 inhibits the ERK signaling pathway, which in turn affects SMAD4 protein expression levels in the TGF-β/SMAD pathway. MY-673 inhibited cell proliferation, migration and induced apoptosis in vivo and in vitro .
    MY-673
  • HY-N15159

    Cyclic GMP-AMP Synthase STING
    Cladophorol A is a cGAS inhibitor that binds to the conserved adenosine nucleobase binding site of cGAS, thereby blocking its activity. At non-cytotoxic concentrations, Cladophorol A effectively inhibits the overactivation of the cGAS-STING pathway with an IC50 of 370 nM. Cladophorol A holds potential for research on inflammatory diseases related to the overactivation of the cGAS-STING pathway .
    Cladophorol A
  • HY-101098

    PD-1/PD-L1 Inflammation/Immunology
    PD-1-IN-18 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator.
    PD-1-IN-18
  • HY-16587

    IPI-926; Patidegib

    Smo Cancer
    Saridegib is a potent and specific inhibitor of Smoothened (Smo), a key signaling transmembrane protein in the Hedgehog (Hh) pathway.
    Saridegib
  • HY-W111144

    Hedgehog Cancer
    T-1330 (Compound 45) is a Hh pathway inhibitor and reduces Gli1 expression .
    T-1330
  • HY-16587A

    IPI 926 hydrochloride; Patidegib hydrochloride

    Smo Cancer
    Saridegib hydrochloride is a potent and specific inhibitor of Smoothened (Smo), a key signaling transmembrane protein in the Hedgehog (Hh) pathway.
    Saridegib hydrochloride
  • HY-N0371
    Pachymic acid
    3 Publications Verification

    3-O-Acetyltumulosic acid

    Akt ERK Cancer
    Pachymic acid is a lanostrane-type triterpenoid from P. cocos. Pachymic acid inhibits Akt and ERK signaling pathways.
    Pachymic acid
  • HY-N0498
    Nitidine chloride
    3 Publications Verification

    Parasite Apoptosis STAT Topoisomerase ERK FAK p38 MAPK NF-κB Inflammation/Immunology Cancer
    Nitidine chloride, a potential anti-malarial lead compound derived from Zanthoxylum nitidum (Roxb) DC, exerts potent anticancer activity through diverse pathways, including inducing apoptosis, inhibiting STAT3 signaling cascade, DNA topoisomerase 1 and 2A, ERK and c-Src/FAK associated signaling pathway, also has anti-inflammatory activity. Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kB pathway .
    Nitidine chloride
  • HY-P10469

    NF-κB Inflammation/Immunology Cancer
    NBD-2 is an inhibitor of the NEMO-IKKα/β interaction in the NF-κB signaling pathway. NBD-2 specifically inhibits the typical NF-κB signaling pathway in vitro and in vivo, reducing the inflammatory response in lipopolysaccharide (LPS) induced acute lung injury (ALI). NBD-2 exhibits significant anti-inflammatory activity. NBD-2 can be used to study diseases related to NF-κB signaling pathway, including autoimmune diseases, cancer, etc .
    NBD-2
  • HY-15735
    c-Met inhibitor 1
    1 Publications Verification

    c-Met/HGFR Cancer
    c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.
    c-Met inhibitor 1
  • HY-153753

    Wnt Cancer
    Wnt pathway inhibitor 4 (compound 16D) is an anticancer agent that has anti-proliferative activity .
    Wnt pathway inhibitor 4
  • HY-121118
    Coronaridine
    1 Publications Verification

    Wnt Neurological Disease Cancer
    Coronaridine, an iboga type alkaloid, inhibits the wnt signaling pathway by decreasing β-catenin expression .
    Coronaridine
  • HY-129390
    Orelabrutinib
    2 Publications Verification

    ICP-022

    Btk Cancer
    Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK .
    Orelabrutinib
  • HY-116455

    Fluorescent Dye Cancer
    BRD-9526 is a potent and selective Sonic Hedgehog (Shh) pathway inhibitor with potential anti-cancer activity. The mechanism of BRD-9526 is similar in some ways to commonly used inhibitors such as cyclopamine, but is significantly different in other ways. The discovery of BRD-9526 may provide a useful probe for studying complex signaling pathways .
    BRD-9526
  • HY-N11262

    p38 MAPK ERK Inflammation/Immunology
    Sudachitin, a polymethoxyflavone that can be isolated from Citrus sudachi, suppresses lipopolysaccharide-induced inflammatory responses in mouse macrophage-like RAW264 cells. Sudachitin can activate the p38MAPK pathway and inhibit the ERK1/2 pathway in HaCaT cells .
    Sudachitin
  • HY-110247
    TRAF-STOP inhibitor 6877002
    1 Publications Verification

    TNF Receptor NF-κB Cardiovascular Disease Inflammation/Immunology
    TRAF-STOP inhibitor 6877002 is a selective CD40-TRAF6 interaction inhibitor. TRAF-STOP inhibitor 6877002 exerts anti-atherosclerotic activity by blocking the CD40-TRAF6 signaling pathway, inhibiting classical monocyte activation, leukocyte recruitment, and macrophage activation and migration. TRAF-STOP inhibitor 6877002 reduces the phosphorylation levels of signaling intermediates in the canonical NF-κB pathway .
    TRAF-STOP inhibitor 6877002
  • HY-N0498R

    Parasite Apoptosis STAT Topoisomerase ERK FAK p38 MAPK NF-κB Inflammation/Immunology Cancer
    Nitidine (chloride) (Standard) is the analytical standard of Nitidine (chloride). This product is intended for research and analytical applications. Nitidine chloride, a potential anti-malarial lead compound derived from Zanthoxylum nitidum (Roxb) DC, exerts potent anticancer activity through diverse pathways, including inducing apoptosis, inhibiting STAT3 signaling cascade, DNA topoisomerase 1 and 2A, ERK and c-Src/FAK associated signaling pathway. Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kB pathway .
    Nitidine chloride (Standard)
  • HY-10590
    TWS119
    25+ Cited Publications

    GSK-3 Autophagy Neurological Disease Cancer
    TWS119 is an inhibitor of GSK-3β, with an IC50 of 30 nM, and activates the wnt/β-catenin pathway.
    TWS119
  • HY-162970

    Wnt Cancer
    XD23 is a potent osteosarcoma inhibitor that works by downregulating DKK1 and activating the WNT/β-catenin signaling pathway.
    XD23
  • HY-143535

    Androgen Receptor Cancer
    HG122 promotes androgen receptor (AR) degradation through the proteasome pathway inhibiting the castration-resistant prostate cancer.
    HG122